Galcanezumab for the treatment of chronic migraine and medication overuse headache: Real‐world clinical evidence in a severely impaired patient population

BACKGROUND: Galcanezumab is a monoclonal antibody acting against the calcitonin gene‐related peptide approved for the preventive treatment of migraine. The aim of this article is to explore its effectiveness and safety of galcanezumab in chronic migraine (CM) with medication overuse‐headache (MOH)....

Descripción completa

Detalles Bibliográficos
Autores principales: Guerzoni, Simona, Baraldi, Carlo, Castro, Flavia Lo, Cainazzo, Maria Michela, Pani, Luca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10275517/
https://www.ncbi.nlm.nih.gov/pubmed/37208838
http://dx.doi.org/10.1002/brb3.2799

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10275517/
https://www.ncbi.nlm.nih.gov/pubmed/37208838
http://dx.doi.org/10.1002/brb3.2799

Ejemplares similares